ABOS
Price
$2.13
Change
-$0.02 (-0.93%)
Updated
Oct 13, 04:59 PM (EDT)
Capitalization
129.63M
35 days until earnings call
Intraday Buy/Sell Signals
APRE
Price
$1.47
Change
+$0.05 (+3.52%)
Updated
Oct 13, 04:59 PM (EDT)
Capitalization
8.27M
Intraday Buy/Sell Signals
Interact to see
Advertisement

ABOS vs APRE

Header iconABOS vs APRE Comparison
Open Charts ABOS vs APREBanner chart's image
Acumen Pharmaceuticals
Price$2.13
Change-$0.02 (-0.93%)
Volume$5.03K
Capitalization129.63M
Aprea Therapeutics
Price$1.47
Change+$0.05 (+3.52%)
Volume$3.86K
Capitalization8.27M
ABOS vs APRE Comparison Chart in %
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. APRE commentary
Oct 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a StrongBuy and APRE is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 14, 2025
Stock price -- (ABOS: $2.14 vs. APRE: $1.42)
Brand notoriety: ABOS and APRE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 174% vs. APRE: 172%
Market capitalization -- ABOS: $129.63M vs. APRE: $8.27M
ABOS [@Biotechnology] is valued at $129.63M. APRE’s [@Biotechnology] market capitalization is $8.27M. The market cap for tickers in the [@Biotechnology] industry ranges from $104.55B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileAPRE’s FA Score has 2 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • APRE’s FA Score: 2 green, 3 red.
According to our system of comparison, APRE is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 6 TA indicator(s) are bullish while APRE’s TA Score has 4 bullish TA indicator(s).

  • ABOS’s TA Score: 6 bullish, 5 bearish.
  • APRE’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, both ABOS and APRE are a good buy in the short-term.

Price Growth

ABOS (@Biotechnology) experienced а +23.70% price change this week, while APRE (@Biotechnology) price change was -5.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.70%. For the same industry, the average monthly price growth was +14.42%, and the average quarterly price growth was +248.16%.

Reported Earning Dates

ABOS is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+1.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($130M) has a higher market cap than APRE($8.27M). ABOS YTD gains are higher at: 24.419 vs. APRE (-56.839). APRE has higher annual earnings (EBITDA): -14.77M vs. ABOS (-132.35M). ABOS has more cash in the bank: 143M vs. APRE (16.5M). APRE has less debt than ABOS: APRE (0) vs ABOS (30.1M). ABOS (0) and APRE (0) have equivalent revenues.
ABOSAPREABOS / APRE
Capitalization130M8.27M1,572%
EBITDA-132.35M-14.77M896%
Gain YTD24.419-56.839-43%
P/E RatioN/AN/A-
Revenue00-
Total Cash143M16.5M867%
Total Debt30.1M0-
FUNDAMENTALS RATINGS
APRE: Fundamental Ratings
APRE
OUTLOOK RATING
1..100
3
VALUATION
overvalued / fair valued / undervalued
1..100
13
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
86
P/E GROWTH RATING
1..100
4
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSAPRE
RSI
ODDS (%)
Bearish Trend 6 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 6 days ago
84%
Bullish Trend 6 days ago
83%
Momentum
ODDS (%)
Bullish Trend 6 days ago
86%
Bearish Trend 6 days ago
90%
MACD
ODDS (%)
Bullish Trend 6 days ago
77%
Bullish Trend 6 days ago
76%
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
82%
Bearish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
80%
Bearish Trend 6 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend 11 days ago
78%
Declines
ODDS (%)
Bearish Trend 28 days ago
88%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 6 days ago
90%
Bullish Trend 6 days ago
78%
Aroon
ODDS (%)
Bearish Trend 6 days ago
88%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
APRE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
DRD28.760.73
+2.60%
DRDGOLD Ltd
NVT95.98-1.75
-1.79%
nVent Electric plc
EMX4.86-0.14
-2.80%
EMX Royalty Corp
TDTH0.87-0.05
-5.15%
Trident Digital Tech Holdings Ltd
FGL0.35-0.05
-12.52%
Founder Group Ltd

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with KYTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-4.89%
KYTX - ABOS
43%
Loosely correlated
-6.09%
CELC - ABOS
43%
Loosely correlated
-6.87%
BEAM - ABOS
41%
Loosely correlated
-5.56%
CRBU - ABOS
40%
Loosely correlated
-9.45%
NMRA - ABOS
40%
Loosely correlated
-3.08%
More

APRE and

Correlation & Price change

A.I.dvisor indicates that over the last year, APRE has been loosely correlated with CABA. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if APRE jumps, then CABA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APRE
1D Price
Change %
APRE100%
-3.86%
CABA - APRE
33%
Loosely correlated
-18.60%
PRQR - APRE
32%
Poorly correlated
-3.60%
EYPT - APRE
31%
Poorly correlated
-2.90%
ABOS - APRE
30%
Poorly correlated
-4.89%
DNA - APRE
30%
Poorly correlated
-11.29%
More